文献速递胸部肿瘤放疗

连续每日对比隔日立体定向体部放疗排程治疗I期非小细胞肺癌

Consecutive Daily Versus Every Other Day Stereotactic Body Radiation Therapy Scheduling for Stage I Non-small Cell Lung Cancer.
PubMed 文献 · Adv Radiat Oncol · 2024-09-06

本研究利用美国国家癌症数据库回顾性分析2004至2016年间接受3、4或5次分割立体定向体部放疗(SBRT)的I期非小细胞肺癌患者,比较每日与隔日(QOD)排程的使用趋势及生存关联。共纳入15,269例患者,其中25.7%接受每日SBRT,74.3%接受隔日SBRT;隔日SBRT使用率从2007年的63.2%上升至2016年的78.3%。多变量分析显示每日与隔日排程的总生存无显著差异(aHR 0.99,95%CI 0.94-1.04,P=0.55),但3次分割隔日SBRT与每日相比生存改善(aHR 0.91,95%CI 0.84-0.98,P=0.02),5次分割隔日SBRT与每日相比生存更差(aHR 1.11,95%CI 1.02-1.22,P=0.02)。

要点

  • 隔日SBRT使用率从2007年63.2%升至2016年78.3%,5次分割SBRT从2004年3.7%升至2016年51.4%(均P<.0001)。
  • 每日与隔日SBRT的总生存无显著差异(aHR 0.99,95%CI 0.94-1.04,P=0.55)。
  • 3次分割隔日SBRT较每日生存改善(aHR 0.91,95%CI 0.84-0.98,P=0.02);5次分割隔日较每日生存更差(aHR 1.11,95%CI 1.02-1.22,P=0.02)。

核心结论

  • 隔日SBRT排程的使用频率约为每日排程的3倍,且2012年后隔日5次分割SBRT成为最常见的剂量排程。
  • 3次分割隔日SBRT与每日相比生存改善,而5次分割隔日SBRT与每日相比生存更差。

研究设计与样本

  • 利用美国国家癌症数据库回顾性识别2004至2016年间接受3、4或5次分割SBRT治疗的I期非小细胞肺癌患者。
  • 采用Kaplan-Meier法和Cox回归模型进行生存分析。

主要发现

  • 共纳入15,269例患者,其中3,927例(25.7%)接受每日SBRT,11,342例(74.3%)接受隔日SBRT。
  • 隔日SBRT使用率从2007年的63.2%上升至2016年的78.3%,5次分割SBRT从2004年的3.7%上升至2016年的51.4%(均P<.0001)。
  • 隔日5次分割SBRT在2012至2016年间成为最普遍的排程(2012年28.5%至2016年41.6%)。
  • 每日SBRT排程的显著相关因素包括分割次数、种族、较低收入、较低合并症指数以及在学术/研究机构治疗(均P≤.01)。
  • 每日SBRT的中位生存为37.9个月,隔日SBRT为38.4个月(P=.4)。

关键数值与推荐

  • 多变量分析显示每日与隔日排程的总生存无差异(aHR 0.99,95%CI 0.94-1.04,P=.55)。
  • 5次分割SBRT与3次分割相比生存更差(aHR 1.09,95%CI 1.03-1.15,P=.002)。
  • 3次分割SBRT中,隔日治疗与每日相比生存改善(aHR 0.91,95%CI 0.84-0.98,P=.02)。
  • 5次分割SBRT中,隔日治疗与每日相比生存更差(aHR 1.11,95%CI 1.02-1.22,P=.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The optimal delivery schedule for stereotactic body radiation therapy (SBRT) in treating stage I non-small cell lung cancer (NSCLC) is unknown. This study used the National Cancer Database to examine daily versus every other day (QOD) SBRT scheduling, including trends over time and association with survival. METHODS AND MATERIALS: The National Cancer Database was used to retrospectively identify patients with stage I NSCLC treated with 3-, 4-, or 5-fraction of SBRT between 2004 and 2016. Survival analysis was performed using the Kaplan-Meier method and Cox regression modeling. RESULTS: Of 15,269 patients, 3927 (25.7%) received SBRT daily, and 11,342 (74.3%) received treatment QOD. The use of QOD treatment increased from 63.2% in 2007 to 78.3% in 2016, and 5-fraction SBRT increased from 3.7% in 2004 to 51.4% in 2016 (both P < .0001). QOD 5-fraction became the most prevalent scheduling from 2012 to 2016 (28.5% in 2012 to 41.6% in 2016). Factors significantly associated with daily SBRT scheduling included number of fractions, race, lower income, lower comorbidities, and treatment at academic/research programs (all P ≤ .01).Median survival for daily SBRT was 37.9 months versus 38.4 months for QOD (P = .4). On multivariable analysis, no difference was found in overall survival between daily versus QOD scheduling (adjusted hazard ratio [aHR], 0.99; 95% confidence interval [CI], 0.94-1.04; P = .55). Five-fraction SBRT was associated with worse survival versus 3 fractions (aHR, 1.09; 95% CI, 1.03-1.15; P = .002). With 3-fraction SBRT, QOD treatment was associated with improved survival versus daily treatment (aHR, 0.91; 95% CI, 0.84-0.98; P = .02). With 5-fraction SBRT, QOD treatment was associated with worse survival versus daily treatment (aHR, 1.11; 95% CI, 1.02-1.22; P = .02). CONCLUSIONS: QOD SBRT schedules were more frequently used to treat stage I NSCLC than daily regimens by a factor of 3:1, and QOD 5-fraction SBRT became the most common dose schedule after 2012. Three-fraction QOD SBRT was associated with improved survival versus daily, whereas 5-fraction QOD SBRT was associated with worse survival versus daily.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lin Y, Qureshi MM, Batra S, et al. Consecutive Daily Versus Every Other Day Stereotactic Body Radiation Therapy Scheduling for Stage I Non-small Cell Lung Cancer. Adv Radiat Oncol. 2024. PMID: 39524524. doi:10.1016/j.adro.2024.101625

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。